Zhengye Biotechnology Must Restore $1.00 Bid Price for 10 Consecutive Days by Nov. 25
ZYBT•Zhengye Biotechnology received a Nasdaq notice on May 29 for failing to maintain a minimum $1.00 bid price from April 16 to May 28, 2026. The company has until November 25, 2026 to restore a $1.00 closing bid for ten consecutive business days or face potential delisting.
1. Nasdaq Notice and Rule Violation
Zhengye Biotechnology Holding Limited received a written notification from Nasdaq on May 29, 2026, indicating noncompliance with Listing Rule 5550(a)(2) after its Class A ordinary shares closed below the $1.00 minimum bid price for 30 consecutive business days from April 16 to May 28, 2026.
2. Compliance Deadline and Options
Under Nasdaq Listing Rule 5810(c)(3)(A), Zhengye has 180 calendar days through November 25, 2026 to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. If compliance is not met, the company may pursue additional remedies or face delisting, with a reverse share split as a potential option.
3. Business Overview and Impact
Zhengye’s day-to-day operations remain unaffected by the notice; the company continues manufacturing and selling veterinary vaccines across China and in export markets on its three production floors and 13 vaccine lines. Management is monitoring share performance closely and evaluating strategic measures to meet Nasdaq requirements without disrupting core business activities.
